You are here

Publications

Found 64 results
Sort by: Author Title [ Type (Asc)] Year
Filters: Author is B. Haibe-Kains  [Clear All Filters]
Conference Paper
Sotiriou C, Wirapati P, Loi S, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S19.
Sotiriou C, Desmedt C, Haibe-Kains B, Harris A, Larsimont D, Buyse M, Wirapati P, Delorenzi M, Bontempi G, Piccart MJ, et al. Biological mechanisms that trigger breast cancer (BC) tumor progresion are molecular subtype dependent.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S30.
Equeter C, Ouriaghli EF, Haibe-Kains B, Stamatopoulos B, André F, Lallemand F, Filippov V, Larsimont D, Sotiriou C, Willard-Gallo K, et al. CD4+ T cells infiltrating breast tumors exhibit altered expression of T cell immune response genes in comparison with their counterparts from the lymph node and blood.
Haibe-Kains B, Sotiriou C, Bontempi G. Class Discovery and Class Prediction from Human Cancer Microarray Datasets.
Stamatopoulos B, Haibe-Kains B, Meuleman N, Bron D, Martiat P, Lagneaux L. CLL patient comparison according to Zap70 mRNA level: new prognostic factors, differences in microRNA expression and distinct interaction capacities with the microenvironment.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, Tutt A, Ellis P, Buyse M, Delorenzi M, Piccart M, et al. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC).
Sotiriou C, Haibe-Kains B, Desmedt C, Wirapati P, Durbecq V, Harris A, Larsimont D, Bontempi G, Buyse M, Delorenzi M, et al. Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures.
Sotiriou C, C.Equeter, Ouriaghli EF, Haibe-Kains B, Durbecq V, Larsimont D, Igniatiadis M, Desmedt C, Willard-Gallo K, Piccart MJ, et al. Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes. In: of Oncology JC ASCO Annual Meeting Proceedings. Vol. 20. ASCO Annual Meeting Proceedings. ; 2008. p. .
Desmedt C, Loi SM, Haibe-Kains B, Soree A, Lallemand F, Durbecq V, Larsimont D, Tutt A, Ellis P, Gillett C, et al. Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Samatopoulos B, Equeter C, Haibe-Kains B, Soree A, Sotiriou C, Bron D, Martiat P, Lagneaux L. Gene expression comparison between B cells expressing high and low level of Zap-70 mRNA reveals distinct profiles, potential therapeutic targets and new prognostic factors for Chronic Lymphocytic Leukemia.
Stamatopoulos B, Haibe-Kains B, Meuleman N, Bron D, Martiat P, Lagneaux L. Gene expression profiles based on ZAP70 mRNA level.
Desmedt C, Azambuja E, Di Leo A, Larsimont D, Durbecq V, Antoine D, Lallemand F, Haibe-Kains B, Cardoso F, Nogaret JM, et al. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-monotherapy in estrogen-receptor (ER) negative breast cancer (BC) patients.
Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, et al. Gene Expression Profiling in Breast Cancer Challenges the Existence of Intermediate Histological Grade.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Piette F, Buyse M, Bontempi G, Delorenzi M, Piccart M. Is genomic grading killing histological grading ?. In: Journal of European Breast Cancer. Vol. 4. Journal of European Breast Cancer. ; 2006. p. 177.
Loi S, Sotiriou C, Haibe-Kains B, Lallemand F, Conus N, Piccart MJ, Speed T, McArthur GA. Overcoming tamoxifen resistance in the luminal B subtype by targeting activated HER2 (ERBB2) signaling in the absence of HER2 overexpression: tailoring treatment in hormone responsive breast cancer.
Loi S, Desmedt C, Haibe-Kains B, Lallemand F, Gillett C, Tutt A, Ryder K, Ellis P, Harris A, Smeds J, et al. Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S129.
Loi S, Piccart M, Haibe-Kains B, Desmedt C, A.Harris, Bergh J, Ellis P, Miller L, Liu E, Sotiriou C, et al. Prediction of early distant relapses on tamoxifen in early- stage breast cancer (BC): a potential tool for adjuvant aromatase inhibitor (AI) tailoring.
Desmedt C, Piette F, Cardoso F, Wang Y, Loi S, Lallemand F, Klijn J, Haibe-Kains B, Viale G, Delorenzi M, et al. TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer.
Durbecq V, Toussaint J, Haibe-Kains B, Desmedt C, Rouas G, Larsimont D, Buyse M, Bontempi G, Piccart MJ, Sotiriou C, et al. Transforming genomic grade index (GGI) into a user-friendly qRT-PCR tool which will assist clinicians and patients in optimizing treatment of early breast cancer (BC).
Stamatopoulos B, Heuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, Bron D, Lagneaux L. Zap-70 mRNA expression quantified in B cell by real time PCR is a powerful prognostic factor in Chronic Lymphocytic Leukemia.

Pages

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer